-5%
Previously, migraine pain was thought to result primarily from the dilation of cerebral blood vessels. However, the neurogenic theory of migraine suggests that abnormal activation of trigeminal nerve pathways is the main cause of migraine pain, while vasodilation is a secondary effect.
Although the exact mechanism of action of Lasmiditan is not fully understood, it is believed to work by selectively activating 5-HT (serotonin) receptors located in both the central and peripheral nervous system, particularly on trigeminal neurons. Activation of these receptors leads to hyperpolarization of nerve terminals and inhibition of trigeminal nerve firing, thereby reducing migraine pain.
Lasmiditan has minimal affinity for other serotonin receptor subtypes and does not significantly interact with adrenergic or dopaminergic receptors.
Midita is indicated for the acute treatment of migraine attacks with or without aura in adults.
It is not intended for the prevention of migraine.
Recommended dose: 50 mg, 100 mg, or 200 mg taken orally as needed
Maximum dose: One dose in 24 hours
A second dose for the same migraine attack is not effective
Safety of treating more than 4 migraine attacks per month has not been established
May be taken with or without food
Patients must be able to wait at least 8 hours before driving or operating machinery after taking Midita
Pediatric Use: Safety and effectiveness in children have not been established
Hepatic Impairment:
- Mild to moderate impairment (Child-Pugh A or B): No dose adjustment required
- Severe impairment (Child-Pugh C): Use is not recommended
রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন।